ENV-294治疗中重度哮喘:一项针对成人的12周研究
一项为期12周、随机、双盲、安慰剂对照、平行分组的2期研究,旨在评估ENV-294在中度至重度哮喘成年参与者中的疗效、安全性和药代动力学
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Clinical Operations
- 邮箱:env-294.clinicaltrials@enveda.com
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35209
- 招聘中
- Enveda Investigative Site
-
-
California
-
Los Angeles、California、美国、90025
- 招聘中
- Enveda Investigative Site
-
San Jose、California、美国、95117
- 招聘中
- Enveda Investigative Site
-
West Hills、California、美国、91307
- 招聘中
- Enveda Investigative Site
-
-
Colorado
-
Colorado Springs、Colorado、美国、80907
- 招聘中
- Enveda Investigative Site
-
-
Florida
-
Hialeah、Florida、美国、33012
- 招聘中
- Enveda Investigative Site
-
Miami、Florida、美国、33135
- 招聘中
- Enveda Investigative Site
-
-
Georgia
-
Albany、Georgia、美国、31707
- 招聘中
- Enveda Investigative Site
-
-
Illinois
-
Maryville、Illinois、美国、62062
- 招聘中
- Enveda Investigative Site
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 招聘中
- Enveda Investigative Site
-
-
Kentucky
-
Owensboro、Kentucky、美国、42301
- 招聘中
- Enveda Investigative Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Enveda Investigative Site
-
-
Michigan
-
Southfield、Michigan、美国、48075
- 招聘中
- Enveda Investigative Site
-
-
Missouri
-
St Louis、Missouri、美国、63141
- 招聘中
- Enveda Investigative Site
-
-
New York
-
The Bronx、New York、美国、10455
- 招聘中
- Enveda Investigative Site
-
-
Oregon
-
Clackamas、Oregon、美国、97015
- 招聘中
- Enveda Investigative Site
-
Medford、Oregon、美国、97504
- 招聘中
- Enveda Investigative Site
-
-
South Carolina
-
North Charleston、South Carolina、美国、29406
- 招聘中
- Enveda Investigative Site
-
-
Texas
-
McKinney、Texas、美国、75069
- 招聘中
- Enveda Investigative Site
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- 招聘中
- Enveda Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Able to read, understand, and sign an informed consent form before any study procedures
- Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
- Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
- Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
- Demonstrated bronchodilator reversibility
- ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
- History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care
Exclusion Criteria:
- Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
- History of life-threatening asthma
- Other significant pulmonary disease
- Recent bronchial thermoplasty (within 2 years)
- Uncontrolled current or recurrent concomitant illness
- Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
- Require immunosuppressive medications or frequent systemic corticosteroids
- Current smokers or former smokers with significant smoking history
- Uncontrolled hypertension
- Significant hepatic impairment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
安慰剂比较:Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and Severity of Adverse Events
大体时间:From first dose through approximately 16 weeks
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
From first dose through approximately 16 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Loss of Asthma Control Events
大体时间:Baseline to Week 12
|
Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria |
Baseline to Week 12
|
|
Time to Loss of Asthma Control
大体时间:Baseline to Week 12
|
Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
大体时间:Baseline to Week 12
|
Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
大体时间:Baseline to Week 12
|
Change from Baseline in the Asthma Control Questionnaire (ACQ-5) |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
大体时间:Baseline to Week 12
|
Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ) |
Baseline to Week 12
|
|
Plasma concentration of ENV-294
大体时间:Baseline to Week 12
|
Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug. |
Baseline to Week 12
|
合作者和调查者
调查人员
- 研究主任:Gurpreet Ahluwalia, PhD、Enveda Therapeutics, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.